Biocytogen Pharmaceuticals (Beijing) Future Growth
Future criteria checks 5/6
Biocytogen Pharmaceuticals (Beijing) is forecast to grow earnings and revenue by 109.2% and 21.5% per annum respectively. EPS is expected to grow by 109.6% per annum. Return on equity is forecast to be 15.4% in 3 years.
Key information
109.2%
Earnings growth rate
109.6%
EPS growth rate
| Biotechs earnings growth | 39.3% |
| Revenue growth rate | 21.5% |
| Future return on equity | 15.4% |
| Analyst coverage | Low |
| Last updated | 30 Aug 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,383 | 182 | N/A | 427 | 2 |
| 12/31/2025 | 1,172 | 98 | N/A | 259 | 2 |
| 12/31/2024 | 947 | -89 | N/A | 311 | 1 |
| 6/30/2024 | 801 | -244 | -156 | -29 | N/A |
| 3/31/2024 | 759 | -313 | -180 | -53 | N/A |
| 12/31/2023 | 717 | -383 | -203 | -77 | N/A |
| 9/30/2023 | 674 | -451 | -304 | -143 | N/A |
| 6/30/2023 | 632 | -519 | -404 | -210 | N/A |
| 3/31/2023 | 583 | -561 | -474 | -256 | N/A |
| 12/31/2022 | 534 | -602 | -544 | -303 | N/A |
| 9/30/2022 | 493 | -585 | -538 | -312 | N/A |
| 6/30/2022 | 453 | -569 | -532 | -320 | N/A |
| 3/31/2022 | 404 | -557 | -548 | -343 | N/A |
| 12/31/2021 | 355 | -546 | -564 | -366 | N/A |
| 12/31/2020 | 254 | -217 | -522 | -225 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2315 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: 2315 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 2315 is expected to become profitable in the next 3 years.
Revenue vs Market: 2315's revenue (21.5% per year) is forecast to grow faster than the Hong Kong market (7.3% per year).
High Growth Revenue: 2315's revenue (21.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2315's Return on Equity is forecast to be low in 3 years time (15.4%).